Tony Skapetis1,2, Constance Law3,4, Rohan Rodricks3,4. 1. Sydney Dental School, Faculty of Medicine and Health, University of Sydney, Westmead Campus, NSW, 2145, Australia. tony.skapetis@sydney.edu.au. 2. Division of Oral Health, Western Sydney Local Health District, Westmead, NSW, Australia. tony.skapetis@sydney.edu.au. 3. Sydney Dental School, Faculty of Medicine and Health, University of Sydney, Westmead Campus, NSW, 2145, Australia. 4. Division of Oral Health, Western Sydney Local Health District, Westmead, NSW, Australia.
Abstract
BACKGROUND: The COVID-19 pandemic has presented extraordinary challenges to worldwide healthcare systems, however, prevalence remains low in some countries. While the challenges of conducting research in high-prevalence countries are well published, there is a paucity from low COVID-19 countries. METHODS: A PRISMA guided systematic review was conducted using the databases Ovid-Medline, Embase, Scopus and Web of Science to identify relevant articles discussing ethical issues relating to research in low prevalence COVID-19 countries. RESULTS: The search yielded 133 original articles of which only 2 fit the inclusion criteria and aim, with neither specific to low prevalence. Most of the available literature focused on clinical management and resource allocation related to high prevalence countries. These results will be discussed under the ethical dimensions of equity, individual liberty, privacy and confidentiality, proportionality, public protection, provision of care, reciprocity, stewardship and trust.. CONCLUSIONS: A systematic review failed to identify articles relating to COVID-19 research ethics, specific to low prevalence countries. It shows that there is a significant gap in the literature that warrants further investigation. Common ethical principles were used to present a distinct set of challenges experienced by a country with a low prevalence of COVID-19. This unique perspective of some of the common ethical problems surrounding research, may help guide further discussion and guide research in similar countries.
BACKGROUND: The COVID-19 pandemic has presented extraordinary challenges to worldwide healthcare systems, however, prevalence remains low in some countries. While the challenges of conducting research in high-prevalence countries are well published, there is a paucity from low COVID-19 countries. METHODS: A PRISMA guided systematic review was conducted using the databases Ovid-Medline, Embase, Scopus and Web of Science to identify relevant articles discussing ethical issues relating to research in low prevalence COVID-19 countries. RESULTS: The search yielded 133 original articles of which only 2 fit the inclusion criteria and aim, with neither specific to low prevalence. Most of the available literature focused on clinical management and resource allocation related to high prevalence countries. These results will be discussed under the ethical dimensions of equity, individual liberty, privacy and confidentiality, proportionality, public protection, provision of care, reciprocity, stewardship and trust.. CONCLUSIONS: A systematic review failed to identify articles relating to COVID-19 research ethics, specific to low prevalence countries. It shows that there is a significant gap in the literature that warrants further investigation. Common ethical principles were used to present a distinct set of challenges experienced by a country with a low prevalence of COVID-19. This unique perspective of some of the common ethical problems surrounding research, may help guide further discussion and guide research in similar countries.
Authors: Connie M Ulrich; Kathleen A Knafl; Sarah J Ratcliffe; Therese S Richmond; Christine Grady; Claiborne Miller-Davis; Gwenyth R Wallen Journal: AJOB Prim Res Date: 2012
Authors: Jessica J Bartoszko; Mohammed Abdul Malik Farooqi; Waleed Alhazzani; Mark Loeb Journal: Influenza Other Respir Viruses Date: 2020-04-21 Impact factor: 4.380
Authors: Daniela Reisz; Iulia Crișan; Andrea Reisz; Raluca Tudor; Doina Georgescu Journal: Int J Environ Res Public Health Date: 2021-12-03 Impact factor: 3.390